4-(苯基甲基)-1-哌嗪乙酸 2-[[2-羟基-3-(2-烯丙-1-基)苯基]亚甲基]酰肼
![4-(苯基甲基)-1-哌嗪乙酸 2-[[2-羟基-3-(2-烯丙-1-基)苯基]亚甲基]酰肼结构式](https://image.chemsrc.com/caspic/332/315183-21-2.png)
4-(苯基甲基)-1-哌嗪乙酸 2-[[2-羟基-3-(2-烯丙-1-基)苯基]亚甲基]酰肼结构式
|
常用名 | 4-(苯基甲基)-1-哌嗪乙酸 2-[[2-羟基-3-(2-烯丙-1-基)苯基]亚甲基]酰肼 | 英文名 | PAC-1 |
|---|---|---|---|---|
| CAS号 | 315183-21-2 | 分子量 | 392.494 | |
| 密度 | 1.1±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C23H28N4O2 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS07, GHS09 |
信号词 | Warning |
|
DL-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase.
Platelets 26 , 736-44, (2015) Aberrant platelet activation plays a critical role in the pathogenesis of heart attack and stroke. DL-3-n-butylphthalide (NBP) has been approved in China to treat stroke with multiple mechanisms. The anti-stroke effects of NBP may be related to its antiplatel... |
|
|
HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi.
Thromb. Haemost. 114 , 994-1003, (2015) High mobility group box 1 (HMGB1) acts as both a nuclear protein that regulates gene expression, as well as a pro-inflammatory alarmin that is released from necrotic or activated cells. Recently, HMGB1-expression in human atherosclerotic plaques was identifie... |
|
|
Detection of HIT antibody dependent platelet aggregation using novel surface imprinting approach.
Talanta 147 , 1-7, (2015) We present a fast, robust and straightforward spin force assisted surface imprinting approach for activated platelets and demonstrate that Heparin induced thrombocytopenia (HIT) platelet aggregation can be measured by this approach. A critical and challenging... |
|
|
Protein C inhibitor (PCI) binds to phosphatidylserine exposing cells with implications in the phagocytosis of apoptotic cells and activated platelets.
PLoS ONE 9(7) , e101794, (2014) Protein C Inhibitor (PCI) is a secreted serine protease inhibitor, belonging to the family of serpins. In addition to activated protein C PCI inactivates several other proteases of the coagulation and fibrinolytic systems, suggesting a regulatory role in hemo... |
|
|
Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets.
J. Thromb. Haemost. 12(5) , 761-72, (2014) Familial platelet disorder with a predisposition to acute myelogenous leukemia (FPD/AML) is an inherited platelet disorder caused by a germline RUNX1 mutation and characterized by thrombocytopenia, a platelet function defect, and leukemia predisposition. The ... |
|
|
In vitro variables of buffy coat-derived platelet concentrates with residual plasma of down to 10% are stably maintained in new-generation platelet additive solutions.
Transfusion 55 , 1700-9, (2015) Platelet additive solutions (PASs) facilitate plasma recovery and may reduce the risk of plasma-associated adverse transfusion reactions. Whereas current apheresis techniques are able to produce platelet concentrates (PCs) with reduced residual plasma volumes... |
|
|
Carmustine induces platelet apoptosis.
Platelets 26 , 437-42, (2015) Carmustine is one of the alkylating chemotherapeutic agents, which are used to treat various types of cancers, such as brain tumors, Hodgkins and non-Hodgkins lymphoma and multiple myeloma. However, carmustine has the side effect of thrombocytopenia, and the ... |
|
|
Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count.
Br. J. Haematol. 165(6) , 854-64, (2014) The pathophysiological mechanisms contributing to the decreased platelet count in immune thrombocytopenia (ITP) are not entirely understood. Here, we investigated the key step of proplatelet formation (PPF) by studying the effect of ITP plasma in thrombopoies... |
|
|
Structure-guided creation of AcAP5-derived and platelet targeted factor Xa inhibitors.
Biochem. Pharmacol. 95 , 253-62, (2015) Anticoagulants and anti-platelet agents are simultaneously administrated in clinical practice (i.e. percutaneous coronary intervention), which cause significant risk of systemic bleeding. Targeted delivery of anticoagulants to the activated platelets at sites... |
|
|
In vitro affinity reduction of biologic response modifiers from production buffy coat platelets exposed to recombinant protein receptors.
Transfusion 55 , 1919-26, (2015) Recent studies link biologic response modifiers found in donor platelet (PLT) concentrates to transfusion reactions. We tested a novel method to deplete BRMs from PLT concentrates using apheresis.Whole blood from 25 donors was treated to yield PLTs for in vit... |